A genetic link specific to risk for childhood leukemia has been identified for the first time, according to a new study.
New research suggests that blocking a protein normally credited with suppressing leukemia may be a promising therapeutic strategy for an aggressive form of the disease called acute myeloid leukemia.
Unique virus-derived particles have been developed that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects.
New research suggests blocking part of a DNA repair complex that helps some types of leukemia resist treatment can increase the effectiveness of chemotherapy and enhance survival.
A biomarker accessible in blood tests has been identified and validated. It could be used to predict which patients who have received stem cell transplants are at the highest risk for the potentially fatal immune response of graft-versus-host disease.
Treatment combining arsenic trioxide with standard care for APL was just as effective as conventional therapy in low-to-intermediate risk disease.
Using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions for acute lymphocytic leukemia patients.
Among patients with CLL, African Americans more commonly present with advanced disease and tend to have shorter survival times than whites despite receiving the same care.
Oral ibrutinib demonstrated durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma in one study, and showed a high frequency of durable remissions in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma in another study.
The drug targets interactions with the tumor microenvironment and promotes remission in patients with relapsed chronic lymphocytic leukemia, according to a study in the New England Journal of Medicine.
Treating patients with pediatric leukemia with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without added heart toxicity, according to a new study.
MicroRNA-155 has been identified as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia whose chromosomes look normal under the microscope.
T cells overexpressing the TRAIL protein destroyed graft-versus-host disease caused by stem cell transplant for leukemia and other cancers.
Gossypol plus navitoclax may be effective in destroying resistant chronic lymphocytic leukemia (CLL) cells in the lymph nodes and bone marrow.
Genetech announced results from CLL11, a Phase 3 study of obinutuzumab (GA101), comparing the combination of either obinutuzumab or Rituxan and chlorambucil to chlorambucil alone in chronic lymphocytic leukemia (CLL).
Gilead announced Phase 2 results for idelalisib, an oral inhibitor of PI3K delta in combination with rituximab for older patients with treatment-naïve chronic lymphocytic leukemia.
The FDA has accepted Seattle Genetics' sBLA for filing of Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Leukemia experts call for examination of the 'right' way to price life-saving drugs
For patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia, activating mutations in the gene encoding the colony stimulating factor 3 receptor are common.
A monoclonal antibody has been found to be cytotoxic to chronic lymphocytic leukemia B cells while having little effect on normal B cells.
Chronic fatigue is more than three times more prevalent among adult survivors of childhood leukemia or lymphoma than among other adults.
Treatment with autologous engineered T cells is effective bridge to potentially curative therapy
Inhibiting the protein receptor Mer destroys cancer cells and enhances chemotherapy in both acute myeloid and acute lymphoblastic leukemia.
Specially treated T cells infused into high-risk and relapsed leukemia patients can prolong survival after stem cell transplantation.
Molecules in the bloodstream that might accurately gauge the likelihood of radiation illness after exposure to ionizing radiation have been identified. This animal study shows that X-rays or gamma rays alter the levels of certain molecules called microRNA (miRNA) in the blood in a predictable way.
Patients with high-risk or relapsed leukemia have been successfully treated with post-stem cell transplantation infusions of large numbers of donor T cells specific for an antileukemic antigen key to prolonging survival, both from the same matched donors.
Persons who have undergone cytotoxic chemotherapy for certain cancers, notably non-Hodgkin lymphoma, may develop acute myeloid leukemia.
Tumors are not factories for the mass production of identical cancer cells, but are, in reality, patchworks of cells with different patterns of gene mutations. A new study shows, more fully than ever before, how these mutations shift and evolve over time.
Removing the Gfi1 protein from acute lymphoid leukemia (ALL) cells weakened and destroyed the cells in mice, researchers discovered.
The risk of developing therapy-related acute myeloid leukemia after chemotherapy varies depending on initial cancer and treatment practices.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|